Coherent Launches ACE FL, an All-New, Two-Micron Fiber Laser to Address the Expanding Opportunities in Urology and Other Medical Markets
Rhea-AI Summary
Coherent (NYSE:COHR) has launched the ACE FL series, a new thulium fiber laser (TFL) designed for medical applications, particularly lithotripsy and benign prostatic hyperplasia (BPH) treatment. The two-micron system offers enhanced precision, better patient outcomes, and improved efficiency compared to traditional holmium:YAG systems.
The ACE FL platform features proprietary fiber designs, superior cutting precision, compact form factor, and enhanced energy efficiency. The system is optimized for integration into surgical devices used in minimally invasive procedures and is complemented by Coherent's range of disposable fiber assemblies.
Positive
- New ACE FL platform offers superior precision and improved patient outcomes
- Product targets expanding market opportunities in urology and medical applications
- Enhanced energy efficiency through lower power consumption
- Vertically integrated manufacturing ensures reliable supply chain
- Proprietary fiber designs protected by IP
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, COHR gained 5.77%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAXONBURG, Pa., June 24, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of its ACE FL series, thulium fiber laser (TFL), engineered specifically for therapeutic medical applications – most notably for lithotripsy and benign prostatic hyperplasia (BPH) treatment.
The new two-micron ACE FL system delivers superior precision, improved patient outcomes, and enhanced procedural efficiency compared to legacy laser technologies such as holmium:YAG systems. It is optimized for integration into surgical devices and laser systems used in minimally invasive procedures.
“Our new thulium fiber laser is a breakthrough platform that enables medical OEMs to deliver safer, faster, and more effective treatments for kidney stones and BPH,” said Martin Seifert, Vice President, High-Power Fiber Laser Business Unit at Coherent. “With the growing shift toward outpatient and minimally invasive procedures, the market opportunity for fiber-based surgical lasers is stronger than ever.”
Thulium fiber lasers offer superior cutting precision in BPH enucleation, a compact form factor ideal for OEM integration, and enhanced energy efficiency through lower power consumption and improved thermal management.
The ACE FL platform leverages proprietary fiber designs and manufacturing capabilities to offer OEM partners a scalable, high-performance solution for next-generation surgical tools. In addition, Coherent enhances rapid ease of integration by multiplying the power of our new ACE FL series with the surgically proven capabilities of our superb range of disposable fiber assemblies.
With vertically integrated manufacturing and IP-protected fiber designs, Coherent is uniquely positioned to support global medical device manufacturers with reliable supply and long-term innovation.
Coherent will showcase the ACE FL at LASER World of Photonics Munich 2025.
About Coherent
Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver innovations that resonate with our customers in diversified applications for the industrial, communications, electronics, and instrumentation markets. Coherent has research and development, manufacturing, sales, service, and distribution facilities worldwide. For more information, please visit us at coherent.com.
Media Contact:
innovations@coherent.com
FAQ
What is Coherent's new ACE FL fiber laser used for?
How does Coherent's ACE FL compare to traditional laser systems?
What are the key advantages of Coherent's new ACE FL laser system?
When will Coherent (COHR) showcase the new ACE FL laser?
What markets is Coherent targeting with the ACE FL laser?
